Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Growth in Short Interest

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 636,900 shares, a growth of 315.5% from the September 15th total of 153,300 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 0.4 days. Approximately 12.5% of the shares of the stock are sold short. Approximately 12.5% of the shares of the stock are sold short. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

EVAX has been the subject of several research reports. Wall Street Zen upgraded Evaxion A/S to a “hold” rating in a research report on Friday, June 27th. HC Wainwright lifted their price objective on Evaxion A/S from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.00.

Institutional Trading of Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. XTX Topco Ltd acquired a new stake in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 16,281 shares of the company’s stock, valued at approximately $30,000. XTX Topco Ltd owned 1.16% of Evaxion A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Stock Down 29.3%

EVAX stock opened at $6.79 on Monday. The stock has a market capitalization of $9.53 million, a P/E ratio of -5.14 and a beta of 0.23. The company has a debt-to-equity ratio of 1.73, a quick ratio of 3.42 and a current ratio of 3.42. Evaxion A/S has a one year low of $1.20 and a one year high of $15.50. The company has a 50 day moving average price of $4.02 and a two-hundred day moving average price of $2.81.

Evaxion A/S (NASDAQ:EVAX) last released its earnings results on Thursday, August 14th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.26). The business had revenue of $0.04 million for the quarter. As a group, sell-side analysts expect that Evaxion A/S will post -0.15 EPS for the current year.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.